Literature DB >> 6330746

Detection of an Epstein-Barr virus-associated membrane antigen in Epstein-Barr virus-transformed nonproducer cells by leukocyte migration inhibition and blocking antibody.

R Szigeti, D Sulitzeanu, G Henle, W Henle, G Klein.   

Abstract

Soluble membrane fractions derived from Raji cells trigger lymphocytes of Epstein-Barr virus (EBV)-seropositive, but not EBV-seronegative, individuals to release a lymphokine that inhibits leukocyte migration. The reaction can be blocked by the sera of patients with EBV-DNA-carrying tumors, Burkitt lymphoma, or nasopharyngeal carcinoma. Absorption of these sera with EBV-positive, but not EBV-negative, cells abrogates their blocking activity. These findings suggest that the antigen responsible for the leukocyte migration inhibition reaction is an EBV-encoded or an EBV-induced membrane component. The antigen is not identical with EBV-associated nuclear antigen or any other known antibody-detected EBV antigen.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6330746      PMCID： PMC345392          DOI： 10.1073/pnas.81.13.4178

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


  16 in total

1.  Cytotoxic effector cells specific for B Cell lines transformed by Epstein-Barr virus are present in patients with infectious mononucleosis.

Authors:  E Svedmyr; M Jondal
Journal:  Proc Natl Acad Sci U S A       Date:  1975-04       Impact factor: 11.205

2.  An EBV-genome-negative cell line established from an American Burkitt lymphoma; receptor characteristics. EBV infectibility and permanent conversion into EBV-positive sublines by in vitro infection.

Authors:  G Klein; B Giovanella; A Westman; J S Stehlin; D Mumford
Journal:  Intervirology       Date:  1975       Impact factor: 1.763

3.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

4.  Demonstration of two distinct components in the early antigen complex of Epstein-Barr virus-infected cells.

Authors:  G Henle; W Henle; G Klein
Journal:  Int J Cancer       Date:  1971-09-15       Impact factor: 7.396

5.  Immunofluorescence in cells derived from Burkitt's lymphoma.

Authors:  G Henle; W Henle
Journal:  J Bacteriol       Date:  1966-03       Impact factor: 3.490

6.  Cellular localization of an Epstein-Barr virus (EBV)-associated complement-fixing antigen in producer and non-producer lymphoblastoid cell lines.

Authors:  B M Reedman; G Klein
Journal:  Int J Cancer       Date:  1973-05       Impact factor: 7.396

7.  Leukocyte migration inhibition studies with Epstein-Barr virus (EBV) determined nuclear antigen (EBNA) in relation to the EBV-carrier status of the donor.

Authors:  R Szigeti; J Luka; G Klein
Journal:  Cell Immunol       Date:  1981-03-01       Impact factor: 4.868

8.  Leukocyte migration inhibition with Epstein-Barr virus negative and positive cell extracts.

Authors:  R Szigeti; L Timár; T Révész
Journal:  Allergy       Date:  1980-03       Impact factor: 13.146

9.  Continuous lymphoid cell lines with characteristics of B cells (bone-marrow-derived), lacking the Epstein-Barr virus genome and derived from three human lymphomas.

Authors:  G Klein; T Lindahl; M Jondal; W Leibold; J Menézes; K Nilsson; C Sundström
Journal:  Proc Natl Acad Sci U S A       Date:  1974-08       Impact factor: 11.205

10.  Phytohaemagglutinin-induced leukocyte migration inhibition and phytohaemagglutinin skin test for screening the cell-mediated immune response in children.

Authors:  R Szigeti; J Bókay; T Révész; D Schuler
Journal:  Allergy       Date:  1980-10       Impact factor: 13.146
View more
  2 in total

1.  A routine method for the establishment of permanent growing lymphoblastoid cell lines.

Authors:  H Neitzel
Journal:  Hum Genet       Date:  1986-08       Impact factor: 4.132

2.  Leukocyte migration inhibition demonstrates a human T-cell response to a membrane protein expressed in latent Epstein-Barr virus infection.

Authors:  D Sulitzeanu; R Szigeti; G Klein; K Hennessy; E Kieff
Journal:  J Virol       Date:  1986-04       Impact factor: 5.103
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.